 |
|
Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Apstein refers to the Dutch GIPS 1 study as the "benchmark study" of GIK, yet this trial failed to demonstrate a significant benefit of GIK infusion in all randomized patients.1 Similarly, a presentation of the recently completed Dutch GIPS 2 study indicated no benefit of GIK on mortality or infarct size in patients with AMI treated early with primary PCI; in fact, the trial was stopped early by the safety monitoring committee because of a potentially higher mortality in the GIK group.2 These data are entirely consistent with the results of CREATE-ECLA,3 which was conducted largely in South America, India, and China, and suggest that interpretation of such trials should be based on their own relative merits, including internal and external validity, rather than on where the trial was conducted.
With regard to the timing of GIK administration, it is noteworthy that in the previous generation of . . . [Full Text of this Article]
Shamir R. Mehta, MD, MSc
smehta@mcmaster.ca
Salim Yusuf, MBBS, DPhil
McMaster University and Population Health Research Institute
Hamilton, Ontario
Rafael Diaz, MD;
Ernesto Paolasso, MD
Estudios Cardiologicos Latinoamerica (ECLA)
Rosario, Argentina
for the CREATE-ECLA Steering Committee
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points
Goyal et al.
Diabetes and Vascular Disease Research 2008;5:276-284.
ABSTRACT
Glucose, insulin, and acute myocardial infarction: reply
Goyal et al.
Eur Heart J 2006;27:2142-2143.
FULL TEXT
|
